US FDA to shorten review time for drug developers under new voucher program
(Reuters) -The U.S. FDA is launching a program under which its commissioner can issue vouchers to companies he finds are aligned with national priorities to shorten their review time for a drug application to one to two months from the typical timeline of about 10-12 months. The regulator said on Tuesday that the commissioner would …
US FDA to shorten review time for drug developers under new voucher program Read More »










